found, through real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry analyses, that restoring JAM-A expression can inhibit the malignant features of thyroid undifferentiated carcinoma (ATC) cell lines, including cell proliferation, motility, and trans-endothelial migration, suggesting that JAM-A could be a potential therapeutic target for thyroid cancer (140). This evidence concerns the gene F11R and thyroid gland undifferentiated (anaplastic) carcinoma.